Reversal of Ventricular Remodeling With Toprol-XL
The purpose of this study is to determine whether treatment with Toprol-XL for 12 months in asymptomatic heart failure subjects will improve their heart structure and thus prevent the progression to symptomatic disease...
Brief Summary
The purpose of this study is to determine whether treatment with Toprol-XL for 12 months in asymptomatic heart failure subjects will improve their heart structure and thus prevent the progression to symptomatic disease.
- Study Type: Interventional
- Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment
- Study Primary Completion Date: September 2003
Intervention(s) in this Clinical Trial
- Drug: Seloken ZOK/Toprol-XL
- 50 mg
- Drug: Seloken ZOK/Toprol-XL
- 200 mg
- Drug: Placebo
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Diagnosis of stable asymptomatic heart failure.
- Documented ejection fraction less than 0.40.
- Must be able to comply with all study procedures.
Exclusion Criteria:
- Taken B-blocker therapy for longer than 1 week within 6 months prior to randomization.
- Have heart problems that would not allow B-blocker therapy.
- Receiving B-blockers therapy for any medical reason including topical B-blockers that might cause systemic absorption (e.g., glaucoma).
- Undergone certain heart surgeries, such as, prior heart transplant or cardiomyoplasty.
- Have certain heart diseases.
- Pregnant or breast feeding.
- Unlikely to survive.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: AstraZeneca Industry
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00038077
Study ID Number: 276
ClinicalTrials.gov Identifier: NCT00038077
Health Authority: United States: Food and Drug Administration
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00038077
